FDA to fast-track Pfizer/Sangamo gene therapy orphan drug – PharmaTimes
PharmaTimes |
FDA to fast-track Pfizer/Sangamo gene therapy orphan drug
PharmaTimes US regulators have granted a Fast Track designation to a potential gene therapy treatment for haemophilia A from Pfizer and Sangamo. SB-525, which also has orphan drug status from the FDA, is one of Sangamo's four lead candidates and is expected to … |
